Jennifer Patel, MD
Allergy & Immunology · Chattanooga, TNNPI 1336381698
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,529 of the $12,118 with a category attached, or 62.1%. 31 manufacturers reported payments, led by Genentech USA, Inc. at 42.2% of the total. Reporting peaked in 2023 at $5,995 and has fallen 74.7% since, to $1,517 in 2025.
Across 376 payments — averaging $32.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$5K
- GSK$1K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$1K
- CSL Behring$758
- Sanofi$565
- plus $2K from 25 others
What the payments were for
- Consulting fees$3,64530%
- Travel & lodging$9458%
- Food & beverage$7,52962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 23 | $5,115 |
| GSK | 87 | $1,324 |
| AstraZeneca | 54 | $1,289 |
| Regeneron Healthcare Solutions, Inc. | 47 | $1,112 |
| CSL Behring | 36 | $758 |
| Sanofi | 28 | $565 |
| Pfizer | 23 | $432 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $311 |
| Novartis | 9 | $171 |
| Grifols USA, LLC | 7 | $142 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $115 |
| Biocryst US Sales Co., LLC | 6 | $112 |
| Teva Pharmaceuticals USA, Inc. | 5 | $74 |
| Octapharma USA, Inc. | 3 | $74 |
| Boehringer Ingelheim | 3 | $54 |
| Aimmune Therapeutics, Inc. | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 4 | $49 |
| Amgen | 2 | $46 |
| Pharming Healthcare, Inc. | 2 | $45 |
| Bio Products Laboratory USA, Inc. | 1 | $45 |
| Merck | 2 | $44 |
| Kaleo, Inc. | 2 | $28 |
| X4 Pharmaceuticals, Inc. | 1 | $26 |
| USWM, LLC | 1 | $24 |
| Optinose US, Inc. | 1 | $20 |
| Biocryst Pharmaceuticals, Inc. | 1 | $18 |
| AbbVie | 1 | $17 |
| Phadia US Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Ionis Pharmaceuticals, Inc. | 1 | $14 |
| Cycle Pharmaceuticals Inc | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,118 in reported general payments places this provider in the 75th percentile of 79 allergy & immunology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 34 | $129,613 |
| XolairOmalizumab | 26 | $78,904 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $54,905 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $8,354 |
| Azelastine Hcl | 126 | $4,468 |
| Epinephrine | 22 | $3,772 |
| Ipratropium Bromide | 70 | $3,468 |
| Arnuity ElliptaFluticasone Furoate | 17 | $3,452 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $2,154 |
| Fluticasone Propionate | 96 | $1,403 |
| Montelukast Sodium | 139 | $1,279 |
| Famotidine | 42 | $975 |
| Ventolin HfaAlbuterol Sulfate | 13 | $722 |
| Hydroxyzine Hcl | 25 | $371 |
| Levocetirizine Dihydrochloride | 36 | $251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,324 | $66,71296 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $3,77222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 79 allergy & immunology providers in Tennessee.
Other allergy & immunology in Chattanooga
- Marc CromieChattanooga$106K
- Todd LevinChattanooga$64K
- Susan RaschalChattanooga$40K
- Lee PerryChattanooga$10K
- Joseph WisniewskiChattanooga$6K
- David ChaffinChattanooga$5K
- Jessica van MasonChattanooga$5K
- Taylor AtchleyChattanooga$4K
- Michael HollieChattanooga$3K
- Paul CarterChattanooga$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.